Atlantanews Online

Delveinsight Business Research LLP

DelveInsight’s “Triple-Negative Breast Cancer (TNBC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Triple-Negative Breast Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Triple-Negative Breast Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Triple-Negative Breast Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Triple-Negative Breast Cancer (TNBC): An Overview

Metastatic Triple Negative Breast Cancer (mTNBC) is defined as a metastatic tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

TNBCs are frequently identified as hyperdense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

TNBC is characterized by various aggressive clinical pathologic features including onset at a younger age, higher mean tumor size, higher-grade tumors, and a higher rate of node positivity. Overall, TNBCs show an aggressive phenotype with a shorter time to relapse and metastatic disease than the more common hormone-receptor-positive invasive ductal carcinomas.

TNBC frequently metastasizes to the viscera, liver, lung, or brain. However, this is not always the case as it may also have an oligometastatic phenotype closer to ER+ BC, with only lymph node and bone disease. TNBC is also heterogeneous in terms of time of recurrence. TNBC has a higher rate of recurrence in the first 5 years and a lower rate of recurrence afterward. The pattern of late recurrence is generally associated with less aggressive disease, frequently with bone metastases.

Triple-Negative Breast Cancer (TNBC) Market Key Facts

• In 2022, the United States accounted for the largest market size among the 7MM countries, making ~61% of the total market size of the 7MM.

• Among the 7MM countries, Spain had the least market size in 2022, accounting for ~3% of the market size in the 7MM region.

• In the EU4 region, Germany accounted for the largest market size, making up ~29% of the total market size of the EU4 region.

• In 2022, among the therapies being administered to first-line patients, KEYTRUDA (pembrolizumab) + paclitaxel/nab-paclitaxel/gemcitabine + carboplatin combination garnered the largest market share in the 7MM region.

• The total incident cases of TNBC in the United States comprised 43,000+ cases in 2022. These cases are expected to increase by 2032.

• Among the EU4 countries, Germany accounted for the highest number of incident cases of TNBC, i.e., 10,700+ cases in 2022. Whereas Spain accounted for the least number of cases, i.e., ~5,200+ cases in 2022.

• In Japan, as per subtype-specific classification, the HER2-negative cases were found to be the highest in number, 8,400+ cases, in 2022.

• As per gene mutation-specific cases, the BRCA1 cases were found to be the highest in number, i.e., 730+ cases in 2022, in the UK.

Triple-Negative Breast Cancer (TNBC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Triple-Negative Breast Cancer pipeline therapies. It also thoroughly assesses the Triple-Negative Breast Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Triple-Negative Breast Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Triple-Negative Breast Cancer (TNBC) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Triple-Negative Breast Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Triple-Negative Breast Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Triple-Negative Breast Cancer Epidemiology, Segmented as –

• Total Incident Cases of Triple Negative Breast Cancer (TNBC)

• Subtype-specific Cases of Triple Negative Breast Cancer (TNBC)

• Gene Mutation-specific Cases of Triple Negative Breast Cancer (TNBC)

• Stage-specific Cases of Triple Negative Breast Cancer (TNBC)

• Age-specific Cases of Triple Negative Breast Cancer (TNBC) 

• Line-wise Treated Cases of Triple Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Triple-Negative Breast Cancer market or expected to be launched during the study period. The analysis covers the Triple-Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Triple-Negative Breast Cancer drugs based on their sale and market share.

The report also covers the Triple-Negative Breast Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Triple-Negative Breast Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Triple-Negative Breast Cancer Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Triple-Negative Breast Cancer (TNBC) Therapeutics Analysis

mTNBC is a type of metastatic breast cancer that does not express the estrogen and progesterone receptors and the human epidermal growth factor receptor type 2 (HER2). Since there are no positive markers to reliably classify TNBC, these tumors are not yet treated with targeted therapies. Perhaps for this reason, they are the most aggressive form of breast carcinomas. The treatment paradigm for mTNBC generally includes a combination of conventional therapies such as surgery, radiation, and chemotherapy.

Currently, the therapeutic market of mTNBC accounts mainly for systemic chemotherapies (either alone or in combination), such as Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc. These chemotherapies are being used off-label, as both first-line and second-line treatment of TNBC patients, with variation in the dosing frequency and drug combinations.

Several major pharma and biotech companies are actively engaged in developing therapies for Triple Negative Breast Cancer (TNBC), collectively contributing to advancements in treatment options. Among these companies, Jiangsu HengRui Medicine stands out with Triple Negative Breast Cancer drug candidates in an advanced stage, specifically in Phase III of clinical trials. This progress signifies a significant step in the development of potential treatments for TNBC, highlighting the industry’s dedication and progress in addressing this medical condition and potentially improving patient outcomes.

Triple-Negative Breast Cancer (TNBC) Companies Actively Working in the Therapeutics Market

Several companies are actively involved in addressing Triple Negative Breast Cancer (TNBC) and advancing treatments and solutions in this field. Some of these companies include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc., and many others.

Emerging and Marketed Triple-Negative Breast Cancer (TNBC) Therapies Covered in the Report Include:

• Camrelizumab: Jiangsu HengRui Medicine

• IPI-549: Infinity Pharmaceuticals

• PMD-026: Phoenix Molecular Designs

• Ipatasertib: Hoffmann-La Roche)

• Pembrolizumab (Imprime PGG): HiberCell

• IPI-549: Infinity Pharmaceuticals

• Leronlimab: CytoDyn

• CFI-400945: Treadwell Therapeutics

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Triple-Negative Breast Cancer Competitive Intelligence Analysis

4. Triple-Negative Breast Cancer Market Overview at a Glance

5. Triple-Negative Breast Cancer Disease Background and Overview

6. Triple-Negative Breast Cancer Patient Journey

7. Triple-Negative Breast Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Triple-Negative Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Triple-Negative Breast Cancer Unmet Needs

10. Key Endpoints of Triple-Negative Breast Cancer Treatment

11. Triple-Negative Breast Cancer Marketed Therapies

12. Triple-Negative Breast Cancer Emerging Drugs and Latest Therapeutic Advances

13. Triple-Negative Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Triple-Negative Breast Cancer Market Outlook (In US, EU5, and Japan)

16. Triple-Negative Breast Cancer Companies Active in the Market

17. Triple-Negative Breast Cancer Access and Reimbursement Overview

18. KOL Views on the Triple-Negative Breast Cancer Market

19. Triple-Negative Breast Cancer Market Drivers

20. Triple-Negative Breast Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hereditary Spastic Paraplegias Market

“Hereditary Spastic Paraplegias Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hereditary Spastic Paraplegias market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hereditary Spastic Paraplegias market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology